Details checkedClinical trial listing onlyHistorical/discontinuedCheckedregistry+company

MED-EL BONEBRIDGE BCI 602 pediatric premarket study

Also known as: BONEBRIDGE BCI 602, BONEBRIDGE, Bone Conduction Implant (BCI), 2023BB006, CIV-24-01-045738, NCT06634784

MED-EL

Primary source

Company

MED-EL

Program Type

Device

Modality

Cochlear/Auditory Implant

Stage

Observational/NA

Status

Completed

Target Gene

—

Route / Mode

Implantable bone-conduction hearing implant

Confidence

88%

Status Confidence

Status needs checking

Evidence Strength

Needs more support

Last Reviewed

2026-06-09

Geography

Germany

Population

pediatric, under-five, conductive-hearing-loss, mixed-hearing-loss, bone-conduction-implant

Trial IDs

Mechanism

Implantable active bone-conduction hearing system evaluated for children under five with conductive or mixed hearing loss; the implant transmits sound through bone conduction to the inner ear.

Indications

Hearing Loss Conductive Hearing Loss Mixed Hearing Loss

Notes

ClinicalTrials.gov verifies this as a MED-EL-sponsored premarket clinical investigation of the BONEBRIDGE BCI 602 in children below five years of age. The previous "BCI/Neurotech" classification was misleading because BCI means bone conduction implant here, not brain-computer interface.

Evidence & Sources

2 structured sources

clinicaltrials

Supports: canonicalName, company, stage, status, indications, populationTags, geography, route...

IDs: NCT06634784, 2023BB006, CIV-24-01-045738

Open

company

Supports: aliases, modality, mechanism, indications, route

IDs: BONEBRIDGE

Open

Key Events

2024-09-25